Informed use of bedaquiline for tuberculosis

The Lancet

Volumn 385, Issue 9979, 2015, Pages 1724-

  Lessem, Erica M ^a   Bernardo, John ^b,d   Reed, Caitlin ^c   Wegener, Donna H ^d  

^a Treatment Action Group   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d National Tuberculosis Controllers Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; QUINOLINE DERIVATIVE;

DRUG INFORMATION; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

DIARYLQUINOLINES; HUMANS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84929051802     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60885-6     Document Type: Letter

References (3)

1. L Ruiz Mingote, D Namutamba, F Apina et al. The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities Lancet 385 2015 477 479
2. US Food and Drug Administration Postmarketing requirements and commitments: Sirturo http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm August 2013 (accessed July 18, 2014).
3. Centers for Disease Control and Prevention Reported tuberculosis in the United States, 2012. Atlanta, USA: 2013 http://www.cdc.gov/tb/statistics/reports/2012/pdf/report2012.pdf (accessed July 18, 2014).